Categories: News

Cannabix Technologies Annual General and Special Meeting Results

VANCOUVER, British Columbia, June 18, 2024 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company”) announces the results of its annual general and special meeting of common shareholders held on June 18, 2024 in Vancouver. Resolutions passed at the meeting included the appointment of Saturna Group Chartered Accountants LLP as auditors for the ensuing year, an ordinary resolution to approve the adoption of the Company’s Stock Option Incentive Plan and the granting of stock options thereunder in an amount up to 15% of the total issued and outstanding shares, an ordinary resolution to approve the adoption of the Company’s Restricted Share Unit Incentive Plan and the granting of equity awards thereunder in an amount up to 5% of the total issued and outstanding shares, and the election of Dr. Raj Attariwala, Dr. Phillip Olla, Rav Mlait, Bryan Loree, and Thomas Clarke as directors.

The Company also reports the cancellation of 1,395,000 stock options exercisable at $0.80.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

21 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

21 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

3 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

4 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

18 hours ago